Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Samiran Panda

Showing results (81-90 of 108) with videos related to

Pageof 11
Sort By:
BMJ Open|January 14, 2025
Incremental cost of treating antimicrobial-resistant infections among hospitalised patients in India: a cohort studyAbhijit Kadam, Megha Mamulwar, Gayatri Bhambure, et al.
The Lancet. Infectious Diseases|January 24, 2021
Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBV152: a double-blind, randomised, phase 1 trialRaches Ella, Krishna Mohan Vadrevu, Harsh Jogdand, et al.
Iscience|February 1, 2021
Immunogenicity and protective efficacy of BBV152, whole virion inactivated SARS- CoV-2 vaccine candidates in the Syrian hamster modelSreelekshmy Mohandas, Pragya D Yadav, Anita Shete-Aich, et al.
Global Mental Health (Cambridge, England)|October 19, 2023
Factors associated with stigma and manifestations experienced by Indian health care workers involved in COVID-19 management in India: A qualitative studyAshoo Grover, U Venkatesh, Jugal Kishore, et al.
The Lancet. Infectious Diseases|March 11, 2021
Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBV152: interim results from a double-blind, randomised, multicentre, phase 2 trial, and 3-month follow-up of a double-blind, randomised phase 1 trialRaches Ella, Siddharth Reddy, Harsh Jogdand, et al.
Scientific Reports|February 3, 2025
Polypharmacy and self-medication among older adults in Indian urban communities-a cross-sectional studySaibal Das, Pavithra Gnanavel, Shalini Smanla, et al.
Lancet (London, England)|November 14, 2021
Efficacy, safety, and lot-to-lot immunogenicity of an inactivated SARS-CoV-2 vaccine (BBV152): interim results of a randomised, double-blind, controlled, phase 3 trialRaches Ella, Siddarth Reddy, William Blackwelder, et al.
Journal of Microbiology, Immunology, and Infection = Wei Mian Yu Gan Ran Za Zhi|July 17, 2022
Delta variant SARS-CoV-2 infections in pediatric cases during the second wave in IndiaPragya D Yadav, Gunjan Kumar, Aparna Mukherjee, et al.
Eclinicalmedicine|December 6, 2021
A phase 2/3, participant-blind, observer-blind, randomised, controlled study to assess the safety and immunogenicity of SII-ChAdOx1 nCoV-19 (COVID-19 vaccine) in adults in IndiaPrasad S Kulkarni, Chandrasekaran Padmapriyadarsini, Johan Vekemans, et al.
The Indian Journal of Medical Research|October 1, 2021
Psychosocial impact of COVID-19 pandemic on healthcare workers in India & their perceptions on the way forward - A qualitative studyTapas Chakma, Beena E Thomas, Simran Kohli, et al.
Pageof 11

Showing results (81-90 of 108) with videos related to

Sort By:
Pageof 11
BMJ Open|January 14, 2025
Incremental cost of treating antimicrobial-resistant infections among hospitalised patients in India: a cohort studyAbhijit Kadam, Megha Mamulwar, Gayatri Bhambure, et al.
The Lancet. Infectious Diseases|January 24, 2021
Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBV152: a double-blind, randomised, phase 1 trialRaches Ella, Krishna Mohan Vadrevu, Harsh Jogdand, et al.
Iscience|February 1, 2021
Immunogenicity and protective efficacy of BBV152, whole virion inactivated SARS- CoV-2 vaccine candidates in the Syrian hamster modelSreelekshmy Mohandas, Pragya D Yadav, Anita Shete-Aich, et al.
Global Mental Health (Cambridge, England)|October 19, 2023
Factors associated with stigma and manifestations experienced by Indian health care workers involved in COVID-19 management in India: A qualitative studyAshoo Grover, U Venkatesh, Jugal Kishore, et al.
The Lancet. Infectious Diseases|March 11, 2021
Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBV152: interim results from a double-blind, randomised, multicentre, phase 2 trial, and 3-month follow-up of a double-blind, randomised phase 1 trialRaches Ella, Siddharth Reddy, Harsh Jogdand, et al.
Scientific Reports|February 3, 2025
Polypharmacy and self-medication among older adults in Indian urban communities-a cross-sectional studySaibal Das, Pavithra Gnanavel, Shalini Smanla, et al.
Lancet (London, England)|November 14, 2021
Efficacy, safety, and lot-to-lot immunogenicity of an inactivated SARS-CoV-2 vaccine (BBV152): interim results of a randomised, double-blind, controlled, phase 3 trialRaches Ella, Siddarth Reddy, William Blackwelder, et al.
Journal of Microbiology, Immunology, and Infection = Wei Mian Yu Gan Ran Za Zhi|July 17, 2022
Delta variant SARS-CoV-2 infections in pediatric cases during the second wave in IndiaPragya D Yadav, Gunjan Kumar, Aparna Mukherjee, et al.
Eclinicalmedicine|December 6, 2021
A phase 2/3, participant-blind, observer-blind, randomised, controlled study to assess the safety and immunogenicity of SII-ChAdOx1 nCoV-19 (COVID-19 vaccine) in adults in IndiaPrasad S Kulkarni, Chandrasekaran Padmapriyadarsini, Johan Vekemans, et al.
The Indian Journal of Medical Research|October 1, 2021
Psychosocial impact of COVID-19 pandemic on healthcare workers in India & their perceptions on the way forward - A qualitative studyTapas Chakma, Beena E Thomas, Simran Kohli, et al.
Pageof 11